SARS-like coronaviruses (SL-CoVs) comprise a diverse group of betacoronaviruses and alphacoronaviruses that infect humans and animal reservoirs, spanning both high-pathogenicity viruses (SARS-CoV) and endemic seasonal coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1). Bat-origin SL-CoVs (RaTG13, SHC014, WIV1, HKU lineages) are the evolutionary reservoir for SARS-CoV and SARS-CoV-2 and are critical to understanding zoonotic spillover risk and pandemic preparedness. All coronaviruses share a common genome architecture encoding spike (S), nucleoprotein (N/NP), membrane (M), and envelope (E) structural proteins, but differ in receptor usage — SARS-CoV and bat SL-CoVs use ACE2, HCoV-229E uses APN/CD13, and HCoV-OC43 uses 9-O-acetylated sialic acid.
Research Use OnlyNot for diagnostic or therapeutic use.
abinScience offers non-SARS-CoV-coronavirus reagents covering SARS-CoV-1, four seasonal human coronaviruses (HCoV-229E, OC43, NL63, HKU1), and bat coronavirus lineages (HKU2, HKU4, HKU5, HKU9) — including recombinant spike/RBD proteins, neutralizing nanobodies, InVivoMAb antibodies, and polyclonal detection antibodies. Manufactured by AtaGenix Laboratories (ISO 9001 & ISO 13485). For SARS-CoV-2-specific reagents, see our dedicated SARS-CoV-2 page.
Note: This page is being reorganized. SARS-CoV-2-specific products are being migrated to their dedicated page. If you are looking for SARS-CoV-2 reagents, please visit that page for the most complete listing.
SARS-CoV (Severe acute respiratory syndrome coronavirus) caused the 2002–2003 epidemic with ~8,000 cases and ~10% fatality rate. Although SARS-CoV has not re-emerged since 2004, its reagents remain essential for pan-sarbecovirus cross-reactivity studies, comparative immunology, and pandemic preparedness research.
Spike / RBD
• SARS-CoV RBD Recombinant Protein (C-His, VK565351) — for cross-reactivity studies with SARS-CoV-2 RBD antibodies
• SARS-CoV Spike Glycoprotein (C-His, VK593011)
• InVivoMAb Anti-SARS-CoV Spike (clone 80R, VK593010) — one of the earliest SARS-CoV neutralizing antibodies identified
• Anti-Spike nanobodies: SAA1322 (VK593013) and SAA1009 (VK593023)
Nucleoprotein (N/NP)
• SARS-CoV NP Recombinant Protein (N-His, VK805052)
• InVivoMAb Anti-SARS-CoV NP (clone CR3018, VK805020)
The four seasonal human coronaviruses (HCoV-229E, OC43, NL63, HKU1) cause 15–30% of common colds and are critical reference viruses for distinguishing SARS-CoV-2 and MERS-CoV serodiagnostics from background immunity.
HCoV-229E (Alphacoronavirus)
• Spike RBD Recombinant Protein (C-His, VK666011)
• Spike neutralizing antibodies: SAA2363 (VK666013), SAA3008 (VK666023), VK666033
• NP Recombinant Protein (N-His, VK612012) and anti-NP pAb (VK612014)
• Membrane Protein (N-His, VK806012)
HCoV-OC43 (Betacoronavirus)
• Membrane protein: M protein N-His (VK677012), M protein N-His variant (VK677022), and anti-M pAb (VK677014)
• Nucleoprotein: NP Recombinant Protein (N-His, VK457012) and anti-NP pAb (VK457014)
Bat coronaviruses are the evolutionary reservoir for all known human-pathogenic sarbecoviruses and merbecoviruses. Reagents targeting bat CoV spike proteins are essential for pandemic preparedness — identifying which bat lineages have pre-adapted RBDs capable of human ACE2 binding.
Bat-CoV HKU2 (Alphacoronavirus, SADS precursor)
• Spike Protein (C-His, VK103011) and NTD (C-Fc, VK103021)
• Spike NTD (N-His, VK103012) and anti-Spike NTD pAb (VK103014)
• Additional proteins: VK103022, VK103024
BtCoV HKU5 (Betacoronavirus, MERS-like)
• RBD Recombinant Protein (C-His, VK003011) and RBD (C-Fc, VK003021)
HCoV-HKU1 (Betacoronavirus, seasonal)
• Spike RBD Protein (C-His, VK038011) and anti-Spike RBD mAb SAA2323 (VK038013)
BtCoV HKU4 & HKU9
• HKU4 (MERS-like): RBD C-His (VK002011) and RBD C-Fc (VK002021)
• HKU9: RBD C-His (VK004011) and RBD C-Fc (VK004021)
Which reagents are useful for pan-coronavirus cross-reactivity studies?
For pan-sarbecovirus studies comparing SARS-CoV, SARS-CoV-2, and bat SL-CoVs: use our SARS-CoV RBD protein (VK565351) alongside SARS-CoV-2 RBD from our SARS-CoV-2 page and bat CoV RBD proteins (HKU4/HKU5/HKU9). For pan-betacoronavirus NP serology: pair SARS-CoV NP (VK805052) with OC43 NP (VK457012) to assess cross-reactive vs. specific responses.
What is the difference between this page and the SARS-CoV-2 page?
This page covers SARS-CoV-1 (2003 epidemic), seasonal human coronaviruses (229E, OC43, NL63, HKU1), and bat coronavirus precursors. Our SARS-CoV-2 page covers 380+ products specific to the COVID-19 pandemic virus. Our MERS-CoV page covers Middle East respiratory syndrome coronavirus.
Do you have reagents for novel bat coronaviruses or newly discovered SL-CoVs?
Our bat CoV portfolio currently covers HKU2, HKU4, HKU5, HKU9, and HKU1 lineages. For emerging bat CoV isolates (e.g., Khosta-2, BANAL-52, RaTG13), contact us — AtaGenix can develop custom recombinant spike/RBD proteins from published sequences within 4–6 weeks.
Explore our complete coronavirus portfolio:
SARS-CoV-2 SL-CoVs / SARS-CoV / Seasonal HCoVs ✓ MERS-CoV MHV (Murine coronavirus) IBV (Avian coronavirus) PDCoV PEDV
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, lambda2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Neutralization
Human
Monoclonal
IgG1, kappa
Iv0221
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, kappa
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, kappa
Plasma, Serum
54.8 pg/mL
125 - 8, 000 pg/mL
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, kappa
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, lambda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, kappa
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1
EY6A
E. coli
P0DTC2 & P0DTC4 & P0DTC5
RBD [Arg319-Phe541] & E [Arg38-Val75] & M [Arg101-Gln222]
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)